1. A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Patients With Hepatic Impairment and Healthy Matched Controls. Issue 5 (27th February 2019) Authors: Shaik, Jafar Sadik B.; Ford, Susan L.; Lou, Yu; Zhang, Zhiping; Bakshi, Kalpana K.; Tenorio, Allan R.; Trezza, Christine; Spreen, William R.; Patel, Parul Journal: Clinical pharmacology in drug development Issue: Volume 8:Issue 5(2019) Page Start: 664 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A Phase I Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Adults With Severe Renal Impairment and Healthy Matched Control Participants. Issue 5 (27th February 2019) Authors: Parasrampuria, Ridhi; Ford, Susan L.; Lou, Yu; Fu, Caifeng; Bakshi, Kalpana K.; Tenorio, Allan R.; Trezza, Christine; Spreen, William R.; Patel, Parul Journal: Clinical pharmacology in drug development Issue: Volume 8:Issue 5(2019) Page Start: 674 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251. (20th February 2017) Authors: Andrews, Chasity D.; Bernard, Leslie St.; Poon, Amanda Yee; Mohri, Hiroshi; Gettie, Natanya; Spreen, William R.; Gettie, Agegnehu; Russell-Lodrigue, Kasi; Blanchard, James; Hong, Zhi; Ho, David D.; Markowitz, Martin Journal: AIDS Issue: Volume 31:Number 4(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans. (1st February 2016) Authors: Bowers, Gary David; Culp, Amanda; Reese, Melinda J.; Tabolt, Glenn; Moss, Lee; Piscitelli, Stephen; Huynh, Phuong; Wagner, David; Ford, Susan L.; Gould, Elizabeth P.; Pan, Rennan; Lou, Yu; Margolis, David A.; Spreen, William R. Journal: Xenobiotica Issue: Volume 46:Number 2(2016:Feb.) Page Start: 147 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Effect of Cabotegravir on Cardiac Repolarization in Healthy Subjects. Issue 6 (22nd June 2016) Authors: Lou, Yu; Buchanan, Ann M.; Chen, Shuguang; Ford, Susan L.; Gould, Elizabeth; Margolis, David; Spreen, William R.; Patel, Parul Journal: Clinical pharmacology in drug development Issue: Volume 5:Issue 6(2016:Nov./Dec.) Page Start: 509 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis. (15th July 2021) Authors: Cutrell, Amy G.; Schapiro, Jonathan M.; Perno, Carlo F.; Kuritzkes, Daniel R.; Quercia, Romina; Patel, Parul; Polli, Joseph W.; Dorey, David; Wang, Yongwei; Wu, Sterling; Van Eygen, Veerle; Crauwels, Herta; Ford, Susan L.; Baker, Mark; Talarico, Christine L.; Clair, Marty St; Jeffrey, Jerry; Whit... Journal: AIDS Issue: Volume 35:Number 9(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy. (1st February 2022) Authors: Mills, Anthony; Richmond, Gary J.; Newman, Cheryl; Osiyemi, Olayemi; Cade, Jerry; Brinson, Cynthia; De Vente, Jerome; Margolis, David A.; Sutton, Kenneth C.; Wilches, Viviana; Hatch, Sarah; Roberts, Jeremy; McCoig, Cynthia; Garris, Cindy; Vandermeulen, Kati; Spreen, William R. Journal: AIDS Issue: Volume 36:Number 2(2022) Page Start: 195 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy. (1st February 2022) Authors: Mills, Anthony; Richmond, Gary J.; Newman, Cheryl; Osiyemi, Olayemi; Cade, Jerry; Brinson, Cynthia; De Vente, Jerome; Margolis, David A.; Sutton, Kenneth C.; Wilches, Viviana; Hatch, Sarah; Roberts, Jeremy; McCoig, Cynthia; Garris, Cindy; Vandermeulen, Kati; Spreen, William R. Journal: AIDS Issue: Volume 36:Number 2(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials. (1st December 2020) Authors: Rizzardini, Giuliano; Overton, Edgar T.; Orkin, Chloe; Swindells, Susan; Arasteh, Keikawus; Górgolas Hernández-Mora, Miguel; Pokrovsky, Vadim; Girard, Pierre-Marie; Oka, Shinichi; Andrade-Villanueva, Jaime F.; Richmond, Gary J.; Baumgarten, Axel; Masiá, Mar; Latiff, Gulam; Griffith, Sandy; Harrin... Journal: Journal of acquired immune deficiency syndromes Issue: Volume 85:Number 4(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Perspectives of healthcare providers on implementation of long‐acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation‐effectiveness study (CUSTOMIZE). Issue 9 (12th September 2022) Authors: Czarnogorski, Maggie; Garris, Cindy P.; Dalessandro, Marybeth; D'Amico, Ronald; Nwafor, Toyin; Williams, Will; Merrill, Deanna; Wang, YuanYuan; Stassek, Larissa; Wohlfeiler, Michael B.; Sinclair, Gary I.; Mena, Leandro A.; Thedinger, Blair; Flamm, Jason A.; Benson, Paul; Spreen, William R. Journal: Journal of the International AIDS Society Issue: Volume 25:Issue 9(2022) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗